Tag Archives: Robert Kane

Cannabis Science CBIS U.S. Federal Government Clearance

Twenty Acre Indoor/Outdoor Cultivation Facility in Northern California in the Final Stages of Escrow Awaiting Transfer of Ownership to Cannabis Science, Inc.

Twenty Acre Indoor/Outdoor Cultivation Facility in Northern California in the Final Stages of Escrow Awaiting Transfer of Ownership to Cannabis Science, Inc.

IRVINE, Calif., Aug. 1, 2016/Weed Wire/ — Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, today announced they are in the final stages of escrow to transfer the 20-acre Northern California cultivation property into its name and commence indoor/outdoor cultivation and production on the land.

Cannabis Science CBIS U.S. Federal Government Clearance

Cannabis Science, Inc. (CBIS) Continues to Support CNN’s Dr. Sanjay Gupta for His Ongoing Efforts to Educate the Public on the Effectiveness of Medical Cannabis for Patients in Need

LOS ANGELES, Feb. 29, 2016 /Weed Wire/ — Cannabis Science, Inc. (OTC PINK: CBIS) continues to support top surgeon and CNN Medical Correspondent Dr. Sanjay Gupta for his historic and high profile work educating the U.S. and the world about the benefits of medical cannabis and support for the medical cannabis community.

Cannabis Science CBIS U.S. Federal Government Clearance

Cannabis Science Targets Successful Autism Treatments and Brings Family Autism Advocate Mieko Hester-Perez on Its Scientific Advisory Board

COLORADO SPRINGS, Colo., Feb. 8, 2016/ Weed Wire/ — Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, today announced its next critical ailment target is autism and brings Mieko Hester-Perez on its Scientific Advisory Board to lead this charge.

Federal Medical Cannabis Legalization Efforts in Congress Motivates Crown Baus Capital to Initiate its Cannabis Drug Development Program With State-by-State Legal Resources

BEVERLY HILLS, Calif., Aug. 1, 2014 /PRNewswire/ — Crown Baus Capital Corp. (OTC: CBCA), a global acquisition-based conglomerate targeting five primary industries: high-tech incubation, drug development, entertainment/media, education, and financial services, sees this week’s Congressional efforts to amend the Controlled Substances Act to permit medical use of cannabis on a nationwide basis as history in the making.


Top